Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 56,055 shares, a drop of 31.8% from the February 26th total of 82,219 shares. Based on an average trading volume of 30,100 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.8% of the company’s shares are short sold.

Lixte Biotechnology Stock Performance

Shares of Lixte Biotechnology stock traded up $0.04 on Monday, reaching $3.13. 39,207 shares of the company’s stock were exchanged, compared to its average volume of 40,278. The company has a market capitalization of $23.41 million, a P/E ratio of -2.65 and a beta of 0.86. Lixte Biotechnology has a 52 week low of $0.64 and a 52 week high of $6.26. The firm’s 50-day moving average is $3.05 and its two-hundred day moving average is $3.91.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lixte Biotechnology currently has an average rating of “Sell”.

Institutional Investors Weigh In On Lixte Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec boosted its position in shares of Lixte Biotechnology by 83.6% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after purchasing an additional 42,530 shares in the last quarter. Renaissance Technologies LLC increased its position in Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after buying an additional 34,350 shares in the last quarter. XTX Topco Ltd acquired a new position in Lixte Biotechnology during the 4th quarter worth approximately $57,000. Axxcess Wealth Management LLC acquired a new position in Lixte Biotechnology during the 4th quarter worth approximately $54,000. Finally, Geode Capital Management LLC boosted its holdings in Lixte Biotechnology by 25.9% in the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares in the last quarter. 5.10% of the stock is owned by institutional investors.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.